The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis

J. Limoges, Larisa Y Poluektova, W. Ratanasuwan, J. Rasmussen, M. Zelivyanskaya, D. R. McClernon, E. R. Lanier, Howard Eliot Gendelman, Y. Persidsky

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Development of anti-retroviral regimens with enhanced efficacy against brain HIV-1 is essential if viral eradication is to be achieved. To address this, a severe combined immune deficiency mouse model of HIV-1 encephalitis was used to assay the effect of protease-containing and protease-sparing drug regimens on viral replication in brain macrophages. Here, HIV-1-infected human monocyte-derived macrophages (MDM) are inoculated into basal ganglia, causing a multinucleated giant cell encephalitis reminiscent of human disease. Drugs were administered at the time of MDM inoculation and continued until sacrifice. Immunohistochemical tests evaluated ongoing viral replication, glial immunity, and neuronal survival. Treatment with ddl/d4T decreased the numbers of infected cells by 75%, while ddl/d4T/amprenavir or ZDV/3TC/ABC diminished infection by 98%. Triple drug regimens decreased astrogliosis by ≥25%. This small-animal model may be used to screen drug regimens that affect ongoing HIV-1 replication within its brain sanctuary.

Original languageEnglish (US)
Pages (from-to)21-34
Number of pages14
JournalVirology
Volume281
Issue number1
DOIs
StatePublished - Mar 1 2001

Fingerprint

Encephalitis
Drug Combinations
HIV-1
Macrophages
Pharmaceutical Preparations
Brain
Peptide Hydrolases
Severe Combined Immunodeficiency
Lamivudine
Giant Cells
Basal Ganglia
Neuroglia
Immunity
Animal Models
Cell Count
Infection

Keywords

  • HIV-1 encephalitis
  • Macrophages
  • Potent anti-retrovirals

ASJC Scopus subject areas

  • Virology

Cite this

Limoges, J., Poluektova, L. Y., Ratanasuwan, W., Rasmussen, J., Zelivyanskaya, M., McClernon, D. R., ... Persidsky, Y. (2001). The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis. Virology, 281(1), 21-34. https://doi.org/10.1006/viro.2000.0758

The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis. / Limoges, J.; Poluektova, Larisa Y; Ratanasuwan, W.; Rasmussen, J.; Zelivyanskaya, M.; McClernon, D. R.; Lanier, E. R.; Gendelman, Howard Eliot; Persidsky, Y.

In: Virology, Vol. 281, No. 1, 01.03.2001, p. 21-34.

Research output: Contribution to journalArticle

Limoges, J, Poluektova, LY, Ratanasuwan, W, Rasmussen, J, Zelivyanskaya, M, McClernon, DR, Lanier, ER, Gendelman, HE & Persidsky, Y 2001, 'The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis', Virology, vol. 281, no. 1, pp. 21-34. https://doi.org/10.1006/viro.2000.0758
Limoges, J. ; Poluektova, Larisa Y ; Ratanasuwan, W. ; Rasmussen, J. ; Zelivyanskaya, M. ; McClernon, D. R. ; Lanier, E. R. ; Gendelman, Howard Eliot ; Persidsky, Y. / The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis. In: Virology. 2001 ; Vol. 281, No. 1. pp. 21-34.
@article{5d8115d6b24e45dc96c99b6eb9bbdeda,
title = "The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis",
abstract = "Development of anti-retroviral regimens with enhanced efficacy against brain HIV-1 is essential if viral eradication is to be achieved. To address this, a severe combined immune deficiency mouse model of HIV-1 encephalitis was used to assay the effect of protease-containing and protease-sparing drug regimens on viral replication in brain macrophages. Here, HIV-1-infected human monocyte-derived macrophages (MDM) are inoculated into basal ganglia, causing a multinucleated giant cell encephalitis reminiscent of human disease. Drugs were administered at the time of MDM inoculation and continued until sacrifice. Immunohistochemical tests evaluated ongoing viral replication, glial immunity, and neuronal survival. Treatment with ddl/d4T decreased the numbers of infected cells by 75{\%}, while ddl/d4T/amprenavir or ZDV/3TC/ABC diminished infection by 98{\%}. Triple drug regimens decreased astrogliosis by ≥25{\%}. This small-animal model may be used to screen drug regimens that affect ongoing HIV-1 replication within its brain sanctuary.",
keywords = "HIV-1 encephalitis, Macrophages, Potent anti-retrovirals",
author = "J. Limoges and Poluektova, {Larisa Y} and W. Ratanasuwan and J. Rasmussen and M. Zelivyanskaya and McClernon, {D. R.} and Lanier, {E. R.} and Gendelman, {Howard Eliot} and Y. Persidsky",
year = "2001",
month = "3",
day = "1",
doi = "10.1006/viro.2000.0758",
language = "English (US)",
volume = "281",
pages = "21--34",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis

AU - Limoges, J.

AU - Poluektova, Larisa Y

AU - Ratanasuwan, W.

AU - Rasmussen, J.

AU - Zelivyanskaya, M.

AU - McClernon, D. R.

AU - Lanier, E. R.

AU - Gendelman, Howard Eliot

AU - Persidsky, Y.

PY - 2001/3/1

Y1 - 2001/3/1

N2 - Development of anti-retroviral regimens with enhanced efficacy against brain HIV-1 is essential if viral eradication is to be achieved. To address this, a severe combined immune deficiency mouse model of HIV-1 encephalitis was used to assay the effect of protease-containing and protease-sparing drug regimens on viral replication in brain macrophages. Here, HIV-1-infected human monocyte-derived macrophages (MDM) are inoculated into basal ganglia, causing a multinucleated giant cell encephalitis reminiscent of human disease. Drugs were administered at the time of MDM inoculation and continued until sacrifice. Immunohistochemical tests evaluated ongoing viral replication, glial immunity, and neuronal survival. Treatment with ddl/d4T decreased the numbers of infected cells by 75%, while ddl/d4T/amprenavir or ZDV/3TC/ABC diminished infection by 98%. Triple drug regimens decreased astrogliosis by ≥25%. This small-animal model may be used to screen drug regimens that affect ongoing HIV-1 replication within its brain sanctuary.

AB - Development of anti-retroviral regimens with enhanced efficacy against brain HIV-1 is essential if viral eradication is to be achieved. To address this, a severe combined immune deficiency mouse model of HIV-1 encephalitis was used to assay the effect of protease-containing and protease-sparing drug regimens on viral replication in brain macrophages. Here, HIV-1-infected human monocyte-derived macrophages (MDM) are inoculated into basal ganglia, causing a multinucleated giant cell encephalitis reminiscent of human disease. Drugs were administered at the time of MDM inoculation and continued until sacrifice. Immunohistochemical tests evaluated ongoing viral replication, glial immunity, and neuronal survival. Treatment with ddl/d4T decreased the numbers of infected cells by 75%, while ddl/d4T/amprenavir or ZDV/3TC/ABC diminished infection by 98%. Triple drug regimens decreased astrogliosis by ≥25%. This small-animal model may be used to screen drug regimens that affect ongoing HIV-1 replication within its brain sanctuary.

KW - HIV-1 encephalitis

KW - Macrophages

KW - Potent anti-retrovirals

UR - http://www.scopus.com/inward/record.url?scp=0035264617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035264617&partnerID=8YFLogxK

U2 - 10.1006/viro.2000.0758

DO - 10.1006/viro.2000.0758

M3 - Article

VL - 281

SP - 21

EP - 34

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -